News summarySEC EDGARNov 3, 2026, 12:00 PM
Zevra Therapeutics, 8-K (2.02, 9.01): reported results of operations
Zevra reported Q3 2026 net revenue of $37.8 million, up 45% year over year, including $34.0 million from MIPLYFFA, net income of $19.2 million, and cash and investments of $270.9 million.